Krogerus advises Herantis Pharma on its First North IPO

Krogerus advised Hermo Pharma and Laurantis Pharma on their combination and the initial public offering and listing of shares in the resulting entity, Herantis Pharma. In its initial public offering, Herantis Pharma issued 1,384,070 new shares at a subscription price of EUR 10.50 per share, amounting to gross proceeds of some EUR 14.3 million. Trading in the company’s shares on First North commenced on 11 June 2014.

Herantis Pharma is a pharmaceutical company specialised in advancing scientific research into clinical research aiming at developing new drugs. The company focuses on diseases with an unmet clinical need. These diseases include dry eye syndrome, Parkinson’s disease, and secondary lymphedema.

Herantis Pharma is the first Finnish drug development company to list since the year 2000.

The transaction was led by partner Tom Fagernäs with the support of counsel Marjukka Sippola. The rest of the Krogerus team included senior associate Kalle Hynönen and associates Simo Autio, Taru Kovanen, Laura Laukkanen, Linda Lindgren, Lauri Raade, Paul Raade and Nikolas Sjöberg.